Issue 59, 2017

FDPP–HA as a theranostic agent for cancer-targeted fluorescence imaging and photodynamic therapy

Abstract

In clinics, for photodynamic therapy (PDT) it is challenging to achieve photosensitizers with properties of high singlet oxygen quantum yield, tumor targeting and fluorescence imaging simultaneously. Herein, a furan flanked diketopyrrolopyrrole (FDPP) molecule, with good singlet oxygen quantum yield (∼26%), is covalently connected to hyaluronic acid (HA) to obtain a water-soluble photosensitizer (FDPP–HA), which presents good specific targeting to HCT-116 tumor cells both in vitro and in vivo. FDPP–HA also exhibits excellent biocompatibility, low dark toxicity and high phototoxicity, which can effectively inhibit the tumor growth in vivo by PDT. The design of FDPP–HA in this work provides a general strategy for cancer target-specific fluorescence imaging and PDT.

Graphical abstract: FDPP–HA as a theranostic agent for cancer-targeted fluorescence imaging and photodynamic therapy

Associated articles

Supplementary files

Article information

Article type
Paper
Submitted
12 Jun 2017
Accepted
21 Jul 2017
First published
27 Jul 2017
This article is Open Access
Creative Commons BY license

RSC Adv., 2017,7, 37369-37373

FDPP–HA as a theranostic agent for cancer-targeted fluorescence imaging and photodynamic therapy

P. Liang, J. Shao, Q. Tang, W. Si, Q. Wang, Q. Zhang and X. Dong, RSC Adv., 2017, 7, 37369 DOI: 10.1039/C7RA06551E

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements